TBPH Theravance Biopharma Inc

Price (delayed)

$10.4

Market cap

$653.79M

P/E Ratio

0.88

Dividend/share

N/A

EPS

$11.85

Enterprise value

$406.94M

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to create transformational medicines to improve the lives ...

Highlights
Theravance Biopharma's debt has shrunk by 92% YoY
Theravance Biopharma's EPS has increased by 5% QoQ
TBPH's equity is down by 8% since the previous quarter
TBPH's revenue is down by 7% year-on-year

Key stats

What are the main financial stats of TBPH
Market
Shares outstanding
62.86M
Market cap
$653.79M
Enterprise value
$406.94M
Valuations
Price to earnings (P/E)
0.88
Price to book (P/B)
1.59
Price to sales (P/S)
14.91
EV/EBIT
0.38
EV/EBITDA
0.38
EV/Sales
7.93
Earnings
Revenue
$51.35M
EBIT
$1.06B
EBITDA
$1.07B
Free cash flow
-$185.7M
Per share
EPS
$11.85
Free cash flow per share
-$2.52
Book value per share
$6.56
Revenue per share
$0.7
TBVPS
$8.25
Balance sheet
Total assets
$607.4M
Total liabilities
$165.6M
Debt
$52.16M
Equity
$441.8M
Working capital
$324.75M
Liquidity
Debt to equity
0.12
Current ratio
12.31
Quick ratio
12.02
Net debt/EBITDA
-0.23
Margins
EBITDA margin
2,074.5%
Gross margin
100%
Net margin
1,698.5%
Operating margin
-179.1%
Efficiency
Return on assets
167.2%
Return on equity
1,577.7%
Return on invested capital
176.8%
Return on capital employed
182.7%
Return on sales
2,059.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

TBPH stock price

How has the Theravance Biopharma stock price performed over time
Intraday
-1.79%
1 week
-1.52%
1 month
2.67%
1 year
5.37%
YTD
-7.31%
QTD
-7.31%

Financial performance

How have Theravance Biopharma's revenue and profit performed over time
Revenue
$51.35M
Gross profit
$51.35M
Operating income
-$91.96M
Net income
$872.13M
Gross margin
100%
Net margin
1,698.5%
The operating income has soared by 64% YoY and by 32% QoQ
Theravance Biopharma's operating margin has surged by 62% YoY and by 32% QoQ
TBPH's revenue is down by 7% year-on-year
The gross profit has contracted by 7% YoY

Growth

What is Theravance Biopharma's growth rate over time

Valuation

What is Theravance Biopharma stock price valuation
P/E
0.88
P/B
1.59
P/S
14.91
EV/EBIT
0.38
EV/EBITDA
0.38
EV/Sales
7.93
Theravance Biopharma's EPS has increased by 5% QoQ
TBPH's equity is down by 8% since the previous quarter
The P/S is 24% lower than the 5-year quarterly average of 20.1 but 6% higher than the last 4 quarters average of 14.3
TBPH's revenue is down by 7% year-on-year

Efficiency

How efficient is Theravance Biopharma business performance
The ROIC has grown by 23% from the previous quarter
The company's return on assets fell by 9% QoQ

Dividends

What is TBPH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TBPH.

Financial health

How did Theravance Biopharma financials performed over time
TBPH's current ratio has surged by 189% year-on-year
Theravance Biopharma's total liabilities has shrunk by 77% YoY and by 41% QoQ
Theravance Biopharma's debt is 88% lower than its equity
The debt to equity has soared by 106% YoY and by 9% QoQ
Theravance Biopharma's debt has shrunk by 92% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.